Metastatic Malignant Neoplasm in the Brain
78
16
41
21
Key Insights
Highlights
Success Rate
66% trial completion
Published Results
22 trials with published results (28%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
14.1%
11 terminated out of 78 trials
65.6%
-21.0% vs benchmark
18%
14 trials in Phase 3/4
105%
22 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (78)
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
Mind-Body Intervention in Glioma Couples